Triple agonist drugs like retatrutide target obesity, but what they actually do is intervene across multiple hallmarks of aging simultaneously. Here's the biology behind the biggest shift in longevity pharmacology in a decade.
There is a thought experiment worth running. Imagine a single intervention that simultaneously reduces visceral fat by 24%, lowers systemic inflammatory markers, reverses non-alcoholic fatty liver disease, improves insulin sensitivity to near-normal levels, reduces resting blood pressure, and cuts major adverse cardiovascular events by 20%. What would you call it? A longevity drug? A metabolic reset?
What you'd actually be describing is the combined effects of GLP-1/GIP/glucagon triple agonists — a class of drugs developed for obesity and diabetes that is proving to be something considerably more significant for those interested in extending healthspan. The cardiovascular mortality benefit is real — demonstrated in a 17,000-person randomized controlled trial. The metabolic improvements are real — documented across dozens of Phase 2 and Phase 3 trials.
GLP-1 agonists were introduced as anti-diabetic medications. Exenatide, the first in class, was approved by the FDA in 2005 for type 2 diabetes. For fifteen years, they were categorized as glucose-lowering drugs with a useful side effect of weight reduction. That categorization was always too narrow.
GLP-1 receptors are not located only in the pancreas. They are expressed on cardiomyocytes, in the vasculature, in the kidney, in the brain, and on immune cells. The SELECT trial (Lincoff et al., NEJM 2023) was the turning point. In 17,604 adults with established cardiovascular disease or high risk, semaglutide 2.4 mg weekly reduced MACE by 20% versus placebo over a median follow-up of 3.3 years. Critically, the benefit was partially independent of weight loss magnitude — patients who lost very little weight still showed significant cardiovascular benefit, demonstrating that GLP-1's direct receptor effects on the heart and vasculature contribute to the outcome.
Now add the GIP receptor component (tirzepatide and retatrutide). Then add the glucagon receptor component (retatrutide alone). The question for longevity medicine is: what do these additions contribute beyond what GLP-1 alone achieves?